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Abstract 
Rationale: Stress urinary incontinence is still a "battlefield" for many minimally invasive therapies, but, unfortunately, few can restore 
the anatomical and functional background of this disorder.  
Objective: Assessing the latest minimally invasive procedures of intra and perisphincterian injection of autologous stem cells.  
Method and Result: The first stem cell implantation (myoblasts and /or mature fibroblasts grown and multiplied in the laboratory 
from biopsy samples taken from the pectoralis muscle) in the urethral sphincter was performed on October 18, 2010, in “Fundeni” 
Clinic of Urology and Renal Transplantation, in Romania.  
Discussion: The follow-up at six weeks with the quality of life questionnaires, micturition diary and clinical examination revealed a 
decrease of urine loss from six pads/ day at one per day, which significantly improved the patient’s quality of life according to visual 
analogue scale. Clinical and urodynamic evaluations will continue and will be future scientific topics. 
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Abbreviations: SUI = stress urinary incontinence; TVT = tension free vaginal tape; TVT-O = tension free vaginal tape 
obturator; QoL = quality of life 
 
Introduction 
Although not life threatening, stress urinary 
incontinence (SUI) is certainly a public health problem, 
affecting the quality of life, mainly of the female 
population. It is a symptom/sign/condition defined by 
involuntary loss of urine that occurs during physical 
activity, with the effort of coughing, sneezing, laughing, 
prolonged standing, sexual activity etc. [1] Its prevalence 
reaches alarming rates, about 20% of total female 
population being affected; percentages increasing to 35% 
for those aged over 60 years [2,3]. 
The most important risk factors for SUI are: female sex, 
childbirth, obstetric history, lifestyle, chronic cough 
(chronic bronchitis, asthma), advanced age, estrogen 
status, obesity and history of pelvic surgery [4-8]. 
The normal functioning of the lower urinary tract 
and that of the nervous system assures the urinary 
continence and the act of micturition. Two different 
muscular structures are mainly involved in controlling the 
act of micturition: the urethral sphincter, which controls 
continence and facilitates micturition and the bladder 
muscle layer, the detrusor, which has the unique 
properties of gradually distending to allow the filling of the 
bladder, with minimal pressure increase, followed by 
efficient contraction in order to void. 
Various conditions lead to pelvic floor structures 
dysfunctions, and so the base of the bladder and the 
urethra, weaken, with urinary incontinence during 
increased abdominal pressure (coughing, laughing, 
sneezing, exercise). 
Still, it has been described as a pathological 
entity in which the components of the pelvic floor are not 
affected and still the urine loss persists, the mechanism 
being described as intrinsic sphincter deficiency [1]. 
The management of SUI is not easy, as 
therapeutic approach varies from conservative methods 
including lifestyle changes, medication, pelvic floor 
muscles exercises, electro stimulation, to minimally 
invasive - injection of collagen, suburethral slings 
reserving invasive surgical treatment for complex, 
recurrent cases [9]. Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
  321 © 2011, Carol Davila University Foundation
Method 
The anatomical and functional restoration of the 
pelvic structures is a challenge for many minimally 
invasive therapies, and just a few have succeeded. 
Intrinsic urethral sphincter deficiency and abnormal 
mobility of the urethra emerged as a key mechanism 
underlying the occurrence of this condition, along with 
other pathogenic theories. More recently, according to the 
“trampoline” theory, any structural defect in the pelvic 
ligaments, bones, fascial structures may contribute to the 
impairment of the pelvic muscle cybernetic system [10]. 
However, clinical experience has shown that not all 
lesions have a proportional role in the development of SUI 
and the mechanism of urethral sealing - mainly muscular, 
contributes fundamentally to the achievement of urinary 
continence. It is not a lower density of skeletal muscle 
fibers in the urethral sphincter structure, involved in the 
appearance of SUI? Although there are controversies in 
the literature, many studies showed a reduction in muscle 
fibers density in a category of patients from which we 
have excluded all other pelvic pathologies [11,12]. Thus, 
theoretically an artificial increase of the number of muscle 
fibers in the structure of the urethral sphincter could 
represent an innovative solution. Among the latest 
minimally invasive procedures, the injection of autologous 
stem cell intra and around the intrinsic sphincter is one of 
the most anatomical and functional methods, as seen in 
Figure 1 (myoblasts and/or mature fibroblasts multiplied 
in the laboratory from biopsy samples taken from the 
pectoral muscles) [13]. This method has proven clearly 
superior to the injection of collagen, it is not associated 
with major side effects, has minimal morbidity rates, 
reduced mean hospitalization time and although still 
experimental, it stands to be a promising procedure in the 
near future. The use of stem cells (myoblasts) as implants 
is a paradigm shift of the current treatment for SUI, 
currently based upon using synthetic materials (such as 
polypropylene mesh), that although well tolerated, they 
can never replace the auto/allograft in terms of 
biocompatibility. In addition, the anatomical restoration of 
the defects means a return to the "restitutio ad integrum" 
principle and not just a simple adjustment in order to 
resolve a pelvic static problem. 
 
 
 
 
 
 
 
 
 
 
 
 
 
With over 30 years of clinical experience in renal 
transplantation performed in “Fundeni” Clinic of Urology 
and Renal Transplantation, with pioneers of urodynamic 
studies and surgical treatment of pelvic static disorders in 
Romania working in this Center, our specialists have 
actively participated in the clinical research of female 
pelvic disorders. In addition, the expertise gained in the 
most important Renal Transplantation Center from Central 
and Eastern Europe – the ”Fundeni” allows and provides 
the infrastructure needed for the development of this 
project. 
For every study regarding SUI, selecting patients 
with stress urinary incontinence mainly caused by urethral 
sphincter deficiency is a difficult task. 
Medical history, physical examination in 
conjunction with urodynamic studies are the necessary 
steps to recruit patients in the study group, which later will 
be compared to a control group to whom a standard 
minimally invasive procedure is performed according to 
the guidelines of the Romanian Association of Urology, 
European Association of Urology and International 
Society of Continence. Many variables, such as age, 
performance and estrogen status, medical and surgical 
history, the severity of SUI, previous therapies both 
medical and surgical performed for the treatment of pelvic 
disorders, have to be taken into account to create well 
balanced study groups. Based on clinical evidence and on 
the results obtained from patient’s follow-up, randomized, 
multicenter, well-managed studies will be designed in the 
future,. 
Stem cell implantation in the urethral sphincter 
was performed for the first time in Romania on October 
18, 2010, in “Fundeni” Clinic of Urology and Renal 
Transplantation. The team was led by Professor Dr. 
Ioanel Sinescu and was made up of Dr. Cristian Surcel, 
Dr. Alexandru Iordache, Dr. Calin Chibelean, Dr. Cristian 
Mirvald, Dr. Carmen Savu, Nurse Liviu Andrei and 
Professor Rainer Marksteiner. Standard protocol was 
applied without incidents, the patient being discharged 
after 24 hours. The follow up at six weeks revealed a 
stunning improvement in the patient’s quality of life (QoL) 
and continence rate, certified by clinical examination, QoL 
questionnaires and frequency-volume chart. The leak was 
reduced from six to one pad/day. Clinical and urodynamic 
follow-up continues and will be a future scientific topic. 
From a technical standpoint, the procedure 
involves four major stages: 
1. Selecting patients with SUI with intrinsic 
sphincter insufficiency. 
2. The collection myoblasts from the pectoris 
major muscle, a maneuver easy to perform, with a short 
learning curve. 
3. Isolation of stem cells (myoblasts) and 
multiplying them in cell cultures at the Center of 
Excellence in Cell and Tissue Research in Innsbruck, 
Austria. (Figures 2 and 3) 
 
Fig. 1 Theoretical scheme of stem cells implantation  
(with the permission of Prof. Marksteiner) Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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4. The surgical procedure of stem cells 
implantation in the urethral sphincter. 
It requires a special biopsy device – Sonoject - 
which includes a central piece through which the biopsy is 
being performed, that provides an adapter to a syringe 
containing the cell suspension and a channel for a 20 
MHz circular ultrasound probe that is used to locate the 
external urethral sphincter and to guide the injections. The 
device is fixed to a metal arm that is attached to the 
surgical table (similar to that used in prostate 
brachytherapy) together with a metal cylinder that slides 
manually, on which the “Sonoject “ is locked on. 
The procedure takes place with the patient in 
lithotomy position, under general anesthesia. The pubic 
region, internal thighs and perineal area are sterile 
draped. Before the procedure, the device is assembled 
and tested in a saline solution or sterile water. Thus the 
circular ultrasound probe is calibrated in order to detect 
the needle and its signal. 
The bladder is filled with 200 mL of saline and the device 
is inserted through the urethra. The system is armed so it 
does not move during the maneuver and the surgeon 
identifies the bladder neck, urethra and urethral sphincter 
(Figure 4). Once established the injection site, the cell 
suspension solution is injected on the anterior side of the 
sphincter, in two different semi-circular quadrants. The 
procedure needs 20 different injection sites, with 100 µL 
of solution. At the end of the procedure, the device is 
withdrawn from the urethra and disassembled. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
At least three surgical specialties treat pelvic 
floor pathology. Posterior compartment prolapse and anal 
incontinence are evaluated by the general surgeon or 
proctologist, uterine and vaginal prolapse, dyspareunia by 
the gynecologist and cystocele and low urinary tract 
symptoms by the urologist. Urinary incontinence and 
pelvic floor prolapse are two pathological entities that 
gave birth to the fourth specialist: the urogynecologist. 
The pathogenesis of SUI is multifactorial and so, the 
management is difficult, requiring clinical and therapeutic 
experience and for this reason many patients receive an 
incomplete treatment, which often worsens the clinical 
background or trigger symptoms caused by other 
structures which at the time of presentation were 
compensated. 
Suburethral slings, inserted transobturatory, 
were introduced in Europe several years ago. This 
procedure was carried out by urogynecologist despite the 
absence of long-term data regarding efficiency and the 
rate of healing. The same approach happened with TVT 
(tension free vaginal tape) when they were introduced 
and, although the medium and long term data were 
lacking, they were adopted and became today's gold-
standard treatment for SUI in women.  
According to Abdel-Fattah’s recently published 
series of reports [14,15] that assessed the preferences for 
Fig. 2. Myoblast growth in cell culture -200x, antiDesmine 
staining (With permission from Prof. Marksteiner). 
Fig. 3. Myoblasts fusion to the myotubuli in cell culture -
200x, antiDesmnine staining (with permission from Prof. 
Marksteiner). 
Fig. 4 Urethral sphincter ultrasound - intraoperative aspect Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
  323 © 2011, Carol Davila University Foundation
minimally invasive treatment of SUI, one third of 
respondents considered that TVT-O (tension free vaginal 
tape obturator) is an up-to-date procedure and it must be 
immediately applied, while the others expect the medium 
and long term statistics. Thus, stem-cell- myoblasts 
therapy may represent an alternative in the future, every-
day intervention, in the urologist’s armamentarium. At 
least for the group of patients, to whom, from the 
pathogenic point of view, the deficiency is limited to the 
urethral sphincter, we believe that the urologist’s interest 
should be maximal. The effectiveness of this treatment 
can change the course of therapy and last but not least, 
the accessibility to urological evaluation of patients with 
SUI. 
Treatment is tailored to the patient’s suffering 
and not just treats the leak of urine. In other words, a 
successful therapy includes the main objective 
parameters (dry/wet) and the subjective quality of life 
which is assessed by questionnaires [16]. However, 
understanding the "results" and the statistical methods 
used in their quantification are not homogeneous and 
sufficiently clear in order to remove any controversy. 
Before we compare and decide which the most effective 
procedure is, we should reach a consensus regarding the 
definition of "results", how they should be measured, 
follow-up intervals, etc. Until these issues are clarified, the 
urologist will continue to choose one of the many existing 
procedures and will remain autonomous in his selection. 
Thus, the need for new therapeutic methods, that can 
restore the integrity of the pelvic structures as close as 
possible, is urgent. The Centers of Excellence in Urology 
must develop research programs and be partners in 
multicenter studies in order to obtain solid long term data. 
Thus, new standards will be created that will be approved 
by urologist everywhere. 
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